Diabetes Devices And Drugs Market Growth Fueled by Digital Health

Market size and Overview
Rising prevalence of diabetes, technological advances in continuous glucose monitoring, and increasing healthcare expenditures drive business growth in the Diabetes Devices And Drugs Market. Escalating investments in R&D for novel insulin therapies bolster market trends.

The Global Diabetes Devices And Drugs Market size is estimated to be valued at USD 191.66 Bn in 2025 and is expected to reach USD 373.49 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10% from 2025 to 2032.

Diabetes Devices And Drugs Market Insights report offers a comprehensive view of market revenue streams and emerging challenges, with insights into technology-driven market share shifts. This industry trends analysis underscores market opportunities in connected health and business growth.

Market Segmentation
Core market segments for the Diabetes Devices And Drugs Market include product type, end-user, and distribution channel. Under product type, devices are classified into blood glucose monitors, insulin pumps, and continuous glucose monitors (CGMs); drugs include insulins, oral anti-diabetic drugs, and GLP-1 receptor agonists. CGMs emerged as dominant sub-segment with revenue exceeding USD 22.5 Bn in 2024, while GLP-1 agonists recorded the fastest CAGR of 14% during 2024–2025. By end-user, the hospital segment held the largest share in 2025, with home care showing the most rapid uptake due to telemedicine integration in late 2024. Analysis of the Diabetes Devices And Drugs Market trends in distribution channels indicates online pharmacies leading growth, underpinned by digital subscription models.

Market Drivers
Rapid adoption of digital chronic disease management solutions stands out as a pivotal market driver in the Diabetes Devices And Drugs Market. In 2024, global shipments of continuous glucose monitoring systems grew by 23% YoY, supported by reimbursement policy expansions in the US and Europe. Governmental initiatives like the US Centers for Medicare & Medicaid Services’ telehealth coverage updates in 2025 facilitated wider access to insulin pumps and CGMs. Additionally, smart insulin pens equipped with Bluetooth and AI-based dosing algorithms, introduced by Abbott Laboratories in 2025, boosted patient adherence rates by 28%, according to a 2025 real-world study. Updated market forecast and industry size models further define the market scope for 2026–2032. These digital deployments expanded the serviceable market size by 7% in North America in 2025.

Segment Analysis
A targeted market analysis reveals devices accounted for USD 115.3 Bn in revenue in 2024 within the Diabetes Devices And Drugs Market. Coherent Market Insights research team’s Diabetes Devices And Drugs Market revenue forecast indicates device sub-segment outpacing drug therapies by a 6% margin by mid-2025. Continuous glucose monitors (CGMs) generated approximately USD 22.5 Bn, cementing their dominance, according to Coherent Market Insights research. Insulin pumps followed with USD 18.7 Bn sales. Conversely, the drugs sub-segment saw GLP-1 receptor agonists achieving the fastest growth, with revenue surging 14% year-on-year in 2025, propelled by strong demand for semaglutide formulations.

Consumer Behaviour Insights
Recent market research underscores a shift toward personalised diabetes management, with 68% of surveyed patients in Europe opting for integrated app-based CGM dashboards in 2025. Digital consumption habits are evolving, as a 2024 survey by HealthTech Analytics reported 54% of US patients preferring subscription-based models over one-time device purchases. Sustainability preferences emerged strongly; 42% of respondents in Asia-Pacific cited eco-friendly packaging as a purchase driver. Furthermore, pricing sensitivity remains high, with 60% of payers negotiating volume-based rebates for insulin cartridges in 2025, reflecting market insights into value-based procurement dynamics.

Key Players
Analysis of Diabetes Devices And Drugs Market share highlights leading market companies including Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharma, Sanofi, Novo Nordisk, Medtronic, Roche Diagnostics, Insulet Corporation, Tandem Diabetes Care, Ascensia Diabetes Care, and Johnson & Johnson. In 2024, Abbott Laboratories expanded CGM production capacity in Ireland, boosting annual output by 15%. DexCom launched its G7 sensor in 2025, achieving a 22% uptick in unit shipments within six months. Eli Lilly’s insulin glargine biosimilar launch in late 2024 drove a 9% increase in global drug segment volumes, according to Coherent Market Insights research.

Key Winning Strategies Adopted by Key Players
In 2025, DexCom pioneered open API integration with major diabetes management apps, enabling real-time data sharing and driving a 15% increase in sensor utilization—an advanced market growth strategy that sets a new standard for interoperability. Abbott Laboratories’ 2025 implementation of biodegradable sensor components reduced product disposal costs by 12%, showcasing an eco-centric innovation rarely seen among peers. Additionally, Eli Lilly’s deployment of AI-driven insulin titration via its SmartDose platform in late 2024 improved dosing accuracy by 22%, reinforcing the impact of digital therapeutics on patient adherence and long-term outcomes.

FAQs
Q1: Who are the dominant players in the Diabetes Devices And Drugs Market?
A1: Leading market players include Abbott Laboratories, DexCom, Inc., Eli Lilly and Company, and Medtronic, with substantial 2024–2025 investments in CGMs, smart pens, and novel GLP-1 therapies driving their dominance.

Q2: What will be the size of the Diabetes Devices And Drugs Market in the coming years?
A2: The market is projected to grow from USD 191.66 Bn in 2025 to approximately USD 372.92 Bn by 2032, at a 10% CAGR, according to our market forecast.

Q3: Which end-user industry has the largest growth opportunity?
A3: Home care settings are poised to expand fastest, with telehealth-enabled monitoring and digital therapeutics uptake accelerating segment growth by 18% year-on-year in 2025.

Q4: How will market development trends evolve over the next five years?
A4: Expect continued proliferation of digital health integrations, AI-driven insulin titration tools, and eco-friendly device designs, shaping the next wave of industry trends.

Q5: What is the nature of the competitive landscape and challenges in the Diabetes Devices And Drugs Market?
A5: The market features intense competition among established pharmaceutical and device manufacturers, with challenges including high R&D costs, regulatory compliance hurdles, and pricing pressures in emerging economies.

Q6: What go-to-market strategies are commonly adopted in the Diabetes Devices And Drugs Market?
A6: Partnerships with tech firms, tiered subscription models for device connectivity, and collaborative reimbursement negotiations are prevalent, enabling faster market penetration and improved patient adherence.

Get more insights on, Diabetes Devices And Drugs Market

Get This Report in Japanese Language: 糖尿病治療機器と医薬品市場

Get This Report in Korean Language: 당뇨병 기기 및 의약품 시장

Read More Articles Related to this Industry- How Semaglutide is Revolutionizing Diabetes Treatment

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)